IL130027A - Rosiglitazone - glyburide synergistic combinations for treatment of diabetes - Google Patents

Rosiglitazone - glyburide synergistic combinations for treatment of diabetes

Info

Publication number
IL130027A
IL130027A IL13002797A IL13002797A IL130027A IL 130027 A IL130027 A IL 130027A IL 13002797 A IL13002797 A IL 13002797A IL 13002797 A IL13002797 A IL 13002797A IL 130027 A IL130027 A IL 130027A
Authority
IL
Israel
Prior art keywords
glyburide
rosiglitazone
diabetes
treatment
synergistic combinations
Prior art date
Application number
IL13002797A
Other languages
English (en)
Other versions
IL130027A0 (en
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IL130027A0 publication Critical patent/IL130027A0/xx
Publication of IL130027A publication Critical patent/IL130027A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13002797A 1997-02-19 1997-12-01 Rosiglitazone - glyburide synergistic combinations for treatment of diabetes IL130027A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3822497P 1997-02-19 1997-02-19
PCT/US1997/021996 WO1998036755A1 (en) 1997-02-19 1997-12-01 Sulfonylurea-glitazone synergistic combinations for diabetes

Publications (2)

Publication Number Publication Date
IL130027A0 IL130027A0 (en) 2000-02-29
IL130027A true IL130027A (en) 2005-09-25

Family

ID=21898725

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13002797A IL130027A (en) 1997-02-19 1997-12-01 Rosiglitazone - glyburide synergistic combinations for treatment of diabetes

Country Status (29)

Country Link
US (2) US5859037A (is)
EP (1) EP0957923A1 (is)
JP (1) JP2001512478A (is)
KR (1) KR20000071179A (is)
CN (1) CN1244801A (is)
AR (1) AR011829A1 (is)
AU (1) AU741215B2 (is)
BG (1) BG103671A (is)
BR (1) BR9714505A (is)
CA (1) CA2272478A1 (is)
CZ (1) CZ289299A3 (is)
EA (1) EA199900725A1 (is)
EE (1) EE9900345A (is)
GT (1) GT199800037A (is)
HN (1) HN1997000167A (is)
HU (1) HUP0001528A3 (is)
IL (1) IL130027A (is)
IS (1) IS5058A (is)
NO (1) NO993982L (is)
NZ (1) NZ336002A (is)
PA (1) PA8447401A1 (is)
PE (1) PE74399A1 (is)
PL (1) PL335166A1 (is)
SK (1) SK111899A3 (is)
SV (1) SV1998000010A (is)
TR (1) TR199902033T2 (is)
UY (1) UY24893A1 (is)
WO (1) WO1998036755A1 (is)
ZA (1) ZA981343B (is)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
UA67743C2 (uk) * 1997-06-18 2004-07-15 Смітклайн Бічам П.Л.С. Фармацевтична композиція, що містить тіазолідиндіон і сульфонілсечовину, для лікування діабету
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
WO1998057634A1 (en) * 1997-06-18 1998-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
CA2354053A1 (en) * 1998-12-24 2000-07-06 Metabasis Therapeutics, Inc. A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
DE1100895T1 (de) * 1999-03-15 2001-09-06 The University Of British Columbia, Vancouver Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US20060154864A1 (en) * 1999-11-01 2006-07-13 Emory University Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
US7563775B2 (en) * 2000-11-01 2009-07-21 Betty C. Villafuerte Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
DK1145717T3 (da) * 2000-04-13 2004-08-02 Pfizer Prod Inc Synergistisk virkning af glyburid og milrinon
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6492339B1 (en) 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR20120034211A (ko) 2002-09-20 2012-04-10 안드렉스 랩스 엘엘씨 약제학적 정제
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
NZ546337A (en) 2003-10-31 2009-03-31 Takeda Pharmaceutical Solid preparation comprising an insulin sensitizer such as pioglitazone hydrochloride, an insulin secretagogue such as glimepiride and a polyoxyethylene sorbitan fatty acid ester such as Polysorbate 80
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
US20060188590A1 (en) * 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
TW200722088A (en) * 2005-05-27 2007-06-16 Sankyo Co Diabetes remedy
WO2007028632A2 (en) * 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
WO2007028633A2 (en) * 2005-09-08 2007-03-15 Uutech Limited Treatment of diabetes related obesity
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
ES2576258T3 (es) 2005-12-22 2016-07-06 Takeda Pharmaceutical Company Limited Preparación sólida que contiene un sensibilizador de insulina
WO2008026668A1 (fr) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Composition médicale contenant un agent d'amélioration de la résistance à l'insuline
JP2010523084A (ja) 2007-03-30 2010-07-15 アンブルックス，インコーポレイテッド 修飾ｆｇｆ−２１ポリペプチド
CA2707484C (en) 2007-12-04 2021-08-10 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
JP2012511027A (ja) * 2008-12-04 2012-05-17 チョンシー ユー 高透過性組成物およびその用途
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
ES2525748T3 (es) 2009-11-13 2014-12-29 Toray Industries, Inc. Agente terapéutico o profiláctico para la diabetes
CN103025334B (zh) * 2010-05-24 2016-03-16 澳星医疗私人有限公司 抗糖尿病组合物和方法
EP3834757B1 (en) 2011-01-19 2022-03-09 Fractyl Health, Inc. Devices for the treatment of the small intestine
JP2014533702A (ja) * 2011-11-23 2014-12-15 オージースター セラピューティクス プロプライアタリ リミテッド 改良された相乗作用抗糖尿病組成物
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
JP6167115B2 (ja) 2012-02-27 2017-07-19 フラクティル ラボラトリーズ インコーポレイテッド 組織の治療のための熱切除システム、デバイスおよび方法
EP4218884A3 (en) 2012-04-19 2023-09-13 Fractyl Health, Inc. Tissue expansion devices, systems and methods
WO2014022436A1 (en) 2012-07-30 2014-02-06 Fractyl Laboratories Inc. Electrical energy ablation systems, devices and methods for the treatment of tissue
WO2014026055A1 (en) 2012-08-09 2014-02-13 Fractyl Laboratories Inc. Ablation systems, devices and methods for the treatment of tissue
EP2903626A4 (en) 2012-10-05 2016-10-19 Fractyl Lab Inc METHODS, SYSTEMS AND DEVICES FOR CARRYING OUT MULTIPLE TREATMENTS OF A PATIENT
WO2014197632A2 (en) 2013-06-04 2014-12-11 Fractyl Laboratories, Inc. Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract
EP3043732B1 (en) 2013-09-12 2021-04-07 Fractyl Laboratories, Inc. Systems and devices for treatment of target tissue
AU2014352874B2 (en) 2013-11-22 2019-03-14 Fractyl Health, Inc. Systems, devices and methods for the creation of a therapeutic restriction in the gastrointestinal tract
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
US9844641B2 (en) 2014-07-16 2017-12-19 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
EP3169260B1 (en) * 2014-07-16 2019-09-25 Fractyl Laboratories, Inc. System for treating diabetes and related diseases and disorders
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
TWI705071B (zh) 2014-10-24 2020-09-21 美商必治妥美雅史谷比公司 經修飾之fgf-21多肽及其用途
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法
US20230139684A1 (en) * 2019-11-22 2023-05-04 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
AU706628B2 (en) * 1995-07-03 1999-06-17 Sankyo Company Limited Treatment of arteriosclerosis and xanthoma
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
ZA981343B (en) 1998-11-16
HN1997000167A (es) 1999-02-09
EA199900725A1 (ru) 2000-04-24
UY24893A1 (es) 1998-07-10
EE9900345A (et) 2000-02-15
KR20000071179A (ko) 2000-11-25
CA2272478A1 (en) 1998-08-27
WO1998036755A1 (en) 1998-08-27
CZ289299A3 (cs) 1999-11-17
NO993982D0 (no) 1999-08-18
PE74399A1 (es) 1999-08-20
SK111899A3 (en) 2000-09-12
IS5058A (is) 1999-05-27
US5972973A (en) 1999-10-26
BG103671A (en) 2000-04-28
JP2001512478A (ja) 2001-08-21
NO993982L (no) 1999-08-18
GT199800037A (es) 1999-08-12
HUP0001528A2 (hu) 2000-11-28
IL130027A0 (en) 2000-02-29
AU741215B2 (en) 2001-11-29
HUP0001528A3 (en) 2000-12-28
BR9714505A (pt) 2000-03-21
NZ336002A (en) 2002-03-28
PA8447401A1 (es) 2001-12-14
AR011829A1 (es) 2000-09-13
SV1998000010A (es) 1999-02-02
TR199902033T2 (xx) 2000-02-21
EP0957923A1 (en) 1999-11-24
PL335166A1 (en) 2000-04-10
CN1244801A (zh) 2000-02-16
AU5590898A (en) 1998-09-09
US5859037A (en) 1999-01-12

Similar Documents

Publication Publication Date Title
IL130027A (en) Rosiglitazone - glyburide synergistic combinations for treatment of diabetes
HK1022835A1 (en) Pharmaceutical composition for treatment of diabetes
PL337362A1 (en) Treatment of diabetes by means of thiazolydinone and metformin
EP0879279A4 (en) DIABETE TREATMENT
HK1031174A1 (en) Compositions and methods for treating diabetes
AU7582398A (en) Composition for treating skin conditions
ZA953256B (en) Skin treatment composition
EP1077704A4 (en) COMBINATION THERAPY FOR TREATING DEPRESSION
AP9801414A0 (en) Combination effective for the treatment of impotence
GB9700899D0 (en) Novel treatment
ZA952121B (en) Skin treatment composition
GB9606076D0 (en) Diabetes treatment
PL337510A1 (en) Treatment of diabetes by means of derivatives of thiazolydinone and sulphonylurea
GB2326116B (en) Treatment of chocolate
EP1007041A4 (en) COMPOSITION FOR TREATING PAIN
IL130831A0 (en) Imino-aza-anthracylinone derivatives for the treatment of amyloidosis
AU7247898A (en) Composition for treating pain
GB9703942D0 (en) Grain treatment
AU4107797A (en) Compounds for the treatment and prevention of diabetes
ZA952120B (en) Skin treatment composition
GB9704174D0 (en) Agent for medical treatment
GB0020261D0 (en) Therapeutic treatment
GB2331514B (en) Effluent treatment
GB9618290D0 (en) Treatment of diabetes
GB9609897D0 (en) Treatment of diabetes

Legal Events

Date Code Title Description
MM9K Patent not in force due to non-payment of renewal fees